Cite
HARVARD Citation
Verstovsek, S. et al. (2014). A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 120 (4), pp. 513-520. [Online].